Long-term management of chronic pain with transdermal buprenorphine: A multicenter, open-label, follow-up study in patients from three short-term clinical trials

Clinical Therapeutics

Volumn 28, Issue 6, 2006, Pages 943-952

  Likar, Rudolf ^a   Kayser, Hubertus ^b   Sittl, Reinhard ^c  

^a GENERAL HOSPITAL KLAGENFURT   (Austria)

^b Practice for Anesthesiology and Special Pain Therapy   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

buprenorphine; cancer pain; chronic pain; long acting opioid; transdermal

Indexed keywords

BUPRENORPHINE;

ADULT; AGED; ANALGESIA; ANXIETY DISORDER; ARTICLE; CANCER PAIN; CANCER PATIENT; CHRONIC PAIN; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAPHORESIS; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MICTURITION DISORDER; MULTICENTER STUDY; NAUSEA AND VOMITING; PAIN ASSESSMENT; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SHORT COURSE THERAPY; SIDE EFFECT; SWELLING;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, SUBLINGUAL; ANALGESICS, OPIOID; BUPRENORPHINE; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PAIN;

EID: 33745960058     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.06.012     Document Type: Article

References (28)

1. World Health Organization. Cancer Pain Relief. 2nd ed (1996), WHO, Geneva, Switzerland
2. Robbie D.S. A trial of sublingual buprenorphine in cancer pain. Br J Clin Pharmacol 7 Suppl 3 (1979) 3155-3175
3. Collett B.J. Chronic opioid therapy for non-cancer pain. Br J Anaesth 87 (2001) 133-143
4. Schug S.A., Merry A.F., and Acland R.H. Treatment principles for the use of opioids in pain of nonmalignant origin. Drugs 42 (1991) 228-239
5. Zenz M., Strumpf M., and Tryba M. Long-term oral opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage 7 (1992) 69-77
6. Transtec (buprenorphine transdermal system) (2001), Grünenthal GmbH, Aachen, Germany
7. Jasinski D.R., Pevnick J.S., and Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction. Arch Gen Psychiatry 35 (1978) 501-516
8. Bohme K. Buprenorphine in a transdermal therapeutic system-a new option. Clin Rheumatol 21 Suppl 1 (2002) 513-516
9. Radbruch L. Buprenorphine TDS: Use in daily practice, benefits for patients. Int J Clin Pract Suppl. (2003) 19-22
10. Radbruch L., and Vielvoye-Kerkmeer A. Buprenorphine TDS: The clinical development rationale and results. Int J Clin Pract Suppl. (2003) 15-18
11. Budd K. Buprenorphine and the transdermal system: The ideal match in pain management. Int J Clin Pract Suppl. (2003) 9-14
12. Caplan R.A., and Southam M. Transdermal drug delivery and its application to pain control. Adv Pain Res. 14 (1990) 233-240
13. Finlay I.G., Scott R., and McCardle C.S. Prospective double-blind comparison of buprenorphine and pethidine in ureteric colic. Br Med J (Clip Res Ed) 284 (1982) 1830-1831
14. Heel R.C., Brogden R.N., Speight T.M., and Avery G.S. Buprenorphine: A review of its pharmacological properties and therapeutic efficacy. Drugs 17 (1979) 81-110
15. Cowan A., Lewis J.W., and Macfarlane I.R. Agonist and antagonist properties of buprenorphine, a new antinoci ceptive agent. Br J Pharmacol. 60 (1977) 537-545
16. Leander J.D. Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 26 (1987) 1445-1447
17. Zaki P.A., Keith Jr. D.E., Brine G.A., et al. Ligand-induced changes in surface mu-opioid receptor number: Re lationship to G protein activation?. J Pharmacol Exp Ther. 292 (2000) 1127-1134
18. (Suppl). Walsh S.L., and Eissenberg T. The clinical pharmacology of buprenorphine: Extrapolating from the laboratory to the clinic. Drug Alcohol Depend 70 (2003) S13-S27
19. Böhme K., and Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine trans dermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study. Pain Clinic 15 (2003) 193-202
20. Sittl R., Griessinger N., and Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in pa tients with inadequately controlled chronic pain related to cancer and other disorders: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 25 (2003) 150-168
21. Sorge J., and Sittl R. Transdermal buprenorphine in the treatment of chronic pain: Results of a Phase III, multi-center, randomized, double-blind, placebo-controlled study. Clin Ther. 26 (2004) 1808-1820
22. McQuay H., and Moore A. Pain measurement, study design and validity. An Evidence-Based Resource for Pain Relief (1998), Oxford University Press, Oxford, UK 14-18
23. Available at:. World Medical Association. Declaration of Helsinki. Ethical principles for Medical Research Involving Human Subjects. Accessed (February 20, 2006). http://www.wma.net/e/policy/b3.htm.
24. Weiss S.C., Emanuel L.L., Fairclough D.L., and Emanuel E.J. Understanding the experience of pain in terminally ill patients. Lancet 357 (2001) 1311-1315
25. Nugent M., Davis C., Brooks D., and Ahmedzai S.H. Long-term observations of patients receiving transdermal fentanyl after a randomized trial. J Pain Symptom Manage. 21 (2001) 385-391
26. Mystakidou K., Parpa E., Tsilika E., et al. Long-term management of non-cancer pain with transdermal thera peutic system-fentanyl. J Pain. 4 (2003) 298-306
27. Allan L., Hays H., Jensen N.H., et al. Rendomised crossover trial of transdermal fentanyl and sustained re lease oral morphine for treating chronic non-cancer pain. BMJ 322 (2001) 1134-1135
28. Hanks G.W., Conno F., Cherry N., et al., Expert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain: The EAPC recommendations. Br J Cancer 84 (2001) 587-593